GenMont Biotech (TPE:3164) Other Current Payables: NT$42.7 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:3164 GenMont Biotech Inc TPE:3164
83 GF Score
Price NT$16.30
GF Value NT$26.26
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is GenMont Biotech Other Current Payables?

GenMont Biotech TPE:3164 -1.21% 83 Other Current Payables is NT$42.7 Mil as of Dec. 2025. GuruFocus rates TPE:3164 with a GF Score™ of 83/100 and a GF Value™ of NT$26.26 (Significantly Undervalued). The stock has 5 warning signs investors should review.

GenMont Biotech's Other Current Payables for the quarter that ended in Dec. 2025 was NT$42.7 Mil.

GenMont Biotech's quarterly Other Current Payables increased from Jun. 2025 (NT$34.1 Mil) to Sep. 2025 (NT$38.1 Mil) and increased from Sep. 2025 (NT$38.1 Mil) to Dec. 2025 (NT$42.7 Mil).

GenMont Biotech's annual Other Current Payables declined from Dec. 2023 (NT$71.1 Mil) to Dec. 2024 (NT$43.3 Mil) and declined from Dec. 2024 (NT$43.3 Mil) to Dec. 2025 (NT$42.7 Mil).

GenMont Biotech Other Current Payables Related Terms

GenMont Biotech Other Current Payables Historical Data

* Premium members only.

The historical data trend for GenMont Biotech's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GenMont Biotech Other Current Payables Chart

GenMont Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 56.53 79.66 71.08 43.32 42.72

GenMont Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.32 111.46 34.12 38.13 42.72
TPE:3164
83GF Score
GenMont Biotech Inc TPE:3164
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GenMont Biotech Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of NT$42.7 Mil mean?
GenMont Biotech (TPE:3164) has a Other Current Payables of NT$42.7 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on GenMont Biotech and its competitors.
Is GenMont Biotech's Other Current Payables too high?
GenMont Biotech's current Other Current Payables is NT$42.7 Mil. Overall, GenMont Biotech has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GenMont Biotech's Other Current Payables compare to VRTX and REGN?
GenMont Biotech's Other Current Payables of NT$42.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on GenMont Biotech and its competitors. GenMont Biotech's current Other Current Payables is NT$42.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenMont Biotech stock overvalued right now?
Based on GuruFocus' analysis, GenMont Biotech (TPE:3164) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$26.26, compared to a current price of NT$16.30 — trading 37.9% below its estimated fair value. The current Other Current Payables is NT$42.7 Mil. GenMont Biotech's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For GenMont Biotech (TPE:3164), the current Other Current Payables is NT$42.7 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GenMont Biotech (TPE:3164) Overvalued in 2026?

Based on GuruFocus' analysis, GenMont Biotech stock appears to be undervalued. The current stock price of NT$16.30 is trading 37.9% below its estimated GF Value™ of NT$26.26. GuruFocus considers GenMont Biotech to be Significantly Undervalued.

Key valuation signals for TPE:3164:

  • Other Current Payables: NT$42.7 Mil
  • GF Value™: NT$26.26 vs. price of NT$16.30 (37.9% below fair value)
  • GF Score™: 83/100 with 5 warning signs

No single metric tells the full story. See the TPE:3164 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GenMont Biotech Business Description

Address No. 8 Nanke 7th Road, Tainan Science and Technology Park, Shanhua District, Tainan, TWN, 741014
GenMont Biotech Inc is engaged in the research, development, manufacturing, and selling of a variety of probiotic supplements. The Group mainly engages in the manufacturing and selling of functional foods, its single operating segment.
83GF Score

Get the complete analysis for TPE:3164

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.30
Price
NT$26.26
GF Value